Link4Health: A Combination Strategy for Linkage and Retention, Swaziland (L4H)

October 20, 2021 updated by: Columbia University

LINK4HEALTH: A Combination Approach to Linkage and Retention for HIV (Human Immunodeficiency Virus) Infected Individuals in Swaziland

Despite increased HIV (Human Immunodeficiency Virus) infection testing in Africa, many patients never enroll in subsequent HIV care after testing or remain in care after an initial enrollment. This study's aim is to improve linkage to HIV care and retention in HIV care through the use of feasible, evidence-based, and practical interventions. The study takes place in Swaziland, the country with the highest HIV prevalence (24%) in sub-Saharan Africa. The study will randomize groups of HIV testing sites and affiliated clinics to either standard of care or a combined intervention strategy (CIS) which consists of point-of care CD4 (cluster differentiation 4 (CD4)) testing at time of HIV testing, fast-track HIV medications for those who are eligible for treatment,mobile phone appointment reminders, care bags filled with health prevention materials, and financial incentives. The study outcomes are linkage to and retention in care as well as cost effectiveness, feasibility of interventions, and patient acceptability of interventions.

Study Overview

Detailed Description

Linkage of patients from HIV testing to HIV care programs and their retention once enrolled in care are essential to HIV program effectiveness in terms of prevention of HIV;related morbidity and mortality and prevention of HIV transmission. Linkage and retention rates in HIV programs in sub-Saharan Africa (SSA) are suboptimal, with less than half of patients who test positive successfully linking and remaining in care at 1 year. This study is a two-arm cluster site;randomized trial to compare the effectiveness of a novel combination package of evidence;based interventions, the combination intervention strategy (CIS), compared to standard of care (SOC) on linkage and retention of HIV;positive patients from point of testing to retention in care. CIS will include 1) point of care CD4+ count assays at HIV testing sites; 2) accelerated antiretroviral therapy (ART) initiation for eligible patients; 3) provision of a basic care and prevention package (BCPP); 4) short message service (SMS) reminders for clinic appointments; and 5) financial incentives for linkage and retention. The primary aim is to evaluate the effectiveness of CIS as compared to SOC on the combined outcome of rapid linkage to HIV care within 1 month and retention in care at 12 months among adults testing positive for HIV. Secondary aims include evaluation of the effectiveness of CIS compared to SOC on each of linkage to HIV; retention in care; time to ART initiation; HIV disease progression and mortality; patient acceptability; association between baseline characteristics and outcomes, and comparison of cost effectiveness.

Study Type

Interventional

Enrollment (Actual)

2201

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Swaziland, Swaziland
        • Bhalekane Clinic
      • Swaziland, Swaziland
        • Dvokolwako
      • Swaziland, Swaziland
        • Good Shepherd Hospital
      • Swaziland, Swaziland
        • Hlatikhulu Hospital
      • Swaziland, Swaziland
        • Horo
      • Swaziland, Swaziland
        • Kamfishane
      • Swaziland, Swaziland
        • Lamvelase
      • Swaziland, Swaziland
        • Luyengo Clinic
      • Swaziland, Swaziland
        • Mangweni Clinic
      • Swaziland, Swaziland
        • Mankayane Hospital
      • Swaziland, Swaziland
        • Mashobneni Clinic
      • Swaziland, Swaziland
        • Mbabane Government Hospital
      • Swaziland, Swaziland
        • Mkhuzweni Health Center
      • Swaziland, Swaziland
        • Motshane
      • Swaziland, Swaziland
        • Mpolenjeni Clinic
      • Swaziland, Swaziland
        • Nhlangano Health Center
      • Swaziland, Swaziland
        • Piggs Peak
      • Swaziland, Swaziland
        • Raleigh Fitkin Memorial Hospital
      • Swaziland, Swaziland
        • Siphofaneni Clinc
      • Swaziland, Swaziland
        • Sithobeloa Rural Health Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Age ≥18 years
  • Testing HIV-positive at an HTC (HIV testing and counseling) site within a SU (study unit)
  • Willing to be referred to an HIV care clinic associated with the SU
  • Willing to provide locator information
  • Willing to adhere to study procedures, including a baseline interview, home-based interviews at 1 and 12 months after study enrollment; home-based CD4+ count assessment 12 months after enrollment, and abstraction of data from their medical records.
  • Able to provide informed consent

Exclusion Criteria:

  • Planning on leaving the community where they currently reside in the next 12 months for a period greater than 6 months
  • Enrolled in HIV (Human immunodeficiency virus) care in the past 6 months at any HIV care clinic
  • Currently on ART (antiretroviral therapy)
  • Initiated ART (for any duration) in the past 6 months at any HIV care clinic
  • Does not speak or understand English or si-Swati
  • Reports being currently pregnant at time of study enrollment

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
No Intervention: Standard of Care
Participants will be managed per standard of care following prevailing Swaziland Ministry of Health guidelines.
Experimental: Combined Intervention Strategy
Point-of-care (POC) CD4+ (cluster of differentiation 4) Count Accelerated ART initiation for ART eligible participants Basic care and prevention package Cellular Appointment Reminders and Follow-Up Financial Incentives
Each HIV testing and counseling (HTC) site will be equipped with POC CD4+ testing using PIMA™ Analyser (Inverness), test strips, and reagents. Study staff will obtain 25 microliters of blood via finger prick and process the POC (point-of-care) CD4+ (cluster of differentiation 4) Count' test immediately following the baseline interview. Test results will be recorded on study forms including a referral form that has multiple copies, one copy to be given to the participant, the second sent to the affiliated HIV (Human immunodeficiency virus)care clinic in the study unit, and the third kept by study staff in a locked cabinet with other confidential material. All participants, regardless of the CD4+ result, will be encouraged to enroll in HIV care as soon as they can.
Other Names:
  • PIMA

Accelerated ART initiation for patients with POC CD4+ < 350 cells/uL (micro-liter) within 1 week from testing.

2 counseling sessions (one at time of HTC and other at first HIV clinic visit), and collection of blood for other baseline lab tests, but initiation prior to return of results for patients who do not meet criteria for waiting

Basic care and prevention package (BCPP) provided approximately every three months that includes: condoms; soap, pill box and pictorial education about use of materials and HIV, such as family testing tools and information. Information on BCPP contents and review the educational materials will be provided. An example of educational materials is a family-testing tool to encourage the participant to have all family members tested for HIV. All BCPP items will be replenished every 3 months for all participants, regardless of ART status, beginning at linkage to HIV care.
Other Names:
  • BCPP

SMS (short messaging service) appointment reminders for follow-up appointments.

Telephone call within 7 days of missed appointment for all patients.

Participants will receive a series of financial incentives to support linkage into care within 1 month and retention in care at 6 months and 12 months after testing HIV positive. The value of the financial incentive (FI) will be 80 Swaziland Rand, calculated based on the associated financial costs of traveling to clinic. These incentives will be distributed by through mobile airtime. Participants without mobile phones will be given an alternative incentive of equal value, such as a store voucher.
Other Names:
  • FI (Financial Incentive)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in proportion of participants who both link to care at assigned study unit within 1 month and are retained in care at the designated study unit 12 months after HIV (Human Immunodeficiency Virus) diagnosis
Time Frame: one month after enrollment, 12 months after enrollment

Combined outcome of linkage to HIV care within 1 month after testing HIV positive and retention in care 12 months after testing.

Participants are considered to achieve this outcome if they successfully link to the HIV clinic at their study unit (SU) within 1 month of testing HIV positive and are retained in care at the HIV clinic at their SU 12 months after testing HIV positive, as measured from medical records.

one month after enrollment, 12 months after enrollment

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Proportion of participants successfully linked to care at designated study unit within 1 month of HIV diagnosis
Time Frame: 12 months after enrollment
Linkage to care within 1 month of HIV testing (at any clinic within the assigned study unit).
12 months after enrollment
Proportion of participants retained in care at designated study unit 12 months after HIV diagnosis.
Time Frame: 12 months after enrollment
Retention in care 12 months after HIV testing, independent of linkage at 1 month (at any clinic within the assigned study unit).
12 months after enrollment
Change in proportion of participants successfully linked to care at any HIV care clinic within one month of HIV diagnosis
Time Frame: one month after enrollment, 12 months after enrollment
Proportion of participants successfully linked to care at any HIV care clinic within one month of HIV diagnosis
one month after enrollment, 12 months after enrollment
Median time from HIV testing to initial assessment of ART (antiretroviral) eligibility
Time Frame: 12-months after enrollment
Time from linkage to ART eligibility assessment
12-months after enrollment
Median time from HIV testing to ART eligibility
Time Frame: 12 months after enrollment
Time from HIV testing to ART eligibility
12 months after enrollment
Proportion of participants who consistently engage in care (attend > 75% of scheduled appointments)
Time Frame: 12-months after enrollment
Proportion of participants who consistently engage in care, defined as attend > 75% of scheduled appointments
12-months after enrollment
Change in proportion of participants with new World Health Organization (WHO) Stage III/IV event or hospitalization
Time Frame: 1 month after enrollment,12 months after enrollment
Proportion of participants with new WHO Stage III/IV event or hospitalization
1 month after enrollment,12 months after enrollment
Median CD4+ (cluster difference 4) count and viral load 12 months after HIV diagnosis
Time Frame: 12 months after testing HIV-positive
Median CD4+ cell count 12 months after HIV diagnosis, median viral load 12 months after HIV diagnosis
12 months after testing HIV-positive
Change in Mortality rate
Time Frame: 1 month after enrollment, 12 months after enrollment
Mortality rate 12 months after HIV diagnosis
1 month after enrollment, 12 months after enrollment
Change in proportion of participants reporting interventions were received
Time Frame: 1 month after enrollment, 12 months after enrollment
Proportion of participants, who are randomized to study units receiving CIS, reporting receipt of each intervention
1 month after enrollment, 12 months after enrollment
Proportion of participants reporting that interventions were highly acceptable
Time Frame: 12 months after enrollment
Proportion of participants, who are randomized to study units receiving CIS, reporting that interventions were highly acceptable
12 months after enrollment

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in adjusted risk ratio comparing proportion of participants who both link to care at assigned study unit within one month and are retained in care at designated study unit twelve months after HIV diagnosis
Time Frame: at enrollment, one month after enrollment, 12 months after enrollment
Adjusted risk ratio comparing proportion of participants who both link to care at assigned study unit within one month and are retained in care at designated study unit twelve months after HIV diagnosis, by strata of age, sex, and other socio-demographic variables
at enrollment, one month after enrollment, 12 months after enrollment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Wafaa El-Sadr, MD MPH, ICAP Columbia University
  • Study Director: Charles Azih, MD MPH, Swaziland MOH
  • Study Director: Scott Braithwaite, MD MSc, New York University
  • Study Director: Batya Elul, PhD MD, ICAP Columbia University
  • Study Director: Peter Ehrenkranz, MD MPH, Centers for Disease Control and Prevention
  • Study Director: Matthew Lamb, PhD MPH, ICAP Columbia University
  • Study Director: Margaret McNairy, MD MSc, ICAP Columbia University
  • Study Director: Phumzile Mndzebele, Swaziland MOH
  • Study Director: Ruben Sahabao, MD, ICAP Swaziland

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

August 1, 2013

Primary Completion (Actual)

May 1, 2016

Study Completion (Actual)

October 12, 2021

Study Registration Dates

First Submitted

July 16, 2013

First Submitted That Met QC Criteria

July 19, 2013

First Posted (Estimate)

July 22, 2013

Study Record Updates

Last Update Posted (Actual)

October 22, 2021

Last Update Submitted That Met QC Criteria

October 20, 2021

Last Verified

October 1, 2021

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on HIV (Human Immunodeficiency Virus)

Clinical Trials on POC (point-of-care) CD4+ (cluster of differentiation 4) Count

Subscribe